title: Cyclic neoglycodecapeptides: how to increase their inhibitory activity and selectivity on lectin/toxin binding to a glycoprotein and cells.
abstract: Protein (lectin/toxin)-glycan interaction can be clinically harmful so that the design of inhibitors has become an aim. Cyclic decapeptides are suited as rigid carriers for carbohydrate derivatives. We herein document the bioactivity of sugar headgroups covalently attached to this carrier for the cases of five proteins, i.e. a potent biohazardous plant agglutinin, a leguminous model lectin and three adhesion/growth-regulatory human lectins. They represent the different types of topological organization within the galectin family. The relative inhibitory activities of glycoclusters with the three ligands (galactose, lactose and the disaccharide of the Thomsen-Friedenreich antigen) reflected the affinity of free carbohydrates, hereby excluding an impairment of binding activity by chemical derivatization and conjugation. Headgroup tailoring is thus one route to optimize activity and selectivity of cyclopeptide-based glycoclusters. The increase of ligand density from tetra- to hexadecavalency added a second route. The plant toxin and tandem-repeat-type galectin-4 were especially sensitive to this parameter change. Strategically combining solid-phase assays for screening with analysis of lectin binding to cells in different systems revealed efficient inhibition by distinct glycoclusters, thereby protecting cells from lectin association. Cyclic neoglycodecapeptides thus warrant further study as lectin-directed pharmaceuticals.
authors.affiliation: Institute of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-University, Munich, Germany. Sabine.Andre@lmu.de
authors.forename: Sabine
authors.initials: S
authors.lastname: André
authors.forename: Olivier
authors.initials: O
authors.lastname: Renaudet
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bossu
authors.forename: Pascal
authors.initials: P
authors.lastname: Dumy
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Gabius
mesh_terms: D000818:Animals; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000737:chemistry; D001212:Asialoglycoproteins / Q000737:chemistry*; D001667:Binding, Competitive; D016466:CHO Cells; D045744:Cell Line, Tumor; D006224:Cricetinae; D003412:Cricetulus; D060748:Fetuins; D005690:Galactose / Q000737:chemistry; D006020:Glycopeptides / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D006898:Hydroxylamines / Q000138:chemical synthesis; D055767:Immobilized Proteins / Q000737:chemistry*; D007785:Lactose / Q000737:chemistry; D037102:Lectins / Q000037:antagonists & inhibitors / Q000378:metabolism* / Q000633:toxicity; D010456:Peptides, Cyclic / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology*; D000509:alpha-Fetoproteins / Q000737:chemistry*
chemical_list: D015295:Antigens, Tumor-Associated, Carbohydrate; D001212:Asialoglycoproteins; D060748:Fetuins; D006020:Glycopeptides; D006898:Hydroxylamines; D055767:Immobilized Proteins; D037102:Lectins; D010456:Peptides, Cyclic; D000509:alpha-Fetoproteins; C017029:asialofetuin; C016467:Thomsen-Friedenreich antigen; D007785:Lactose; D005690:Galactose